Hart-Scott-Rodino Review Period For Acquisition Of Medarex Expires

Bristol-Myers Squibb has reported the expiration of Hart-Scott-Rodino (HSR) review period for its tender offer for Medarex.

The expiration of the HSR waiting period satisfies one of the conditions to the tender offer, which will expire on August 24, 2009, unless extended in accordance with the merger agreement and the applicable rules and regulations of the SEC.

The closing of the tender offer remains subject to customary terms and conditions. It includes the tender of a number of shares that, together with the number of shares already owned by Bristol-Myers Squibb, constitutes at least a majority of Medarex’s outstanding shares of common stock.